Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples.
Comparative analysis of circulating tumour cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy
Comparison of CellSearch versus Parsortix circulating tumour cell enumeration and molecular characterisation: A pilot study in metastatic prostate cancer patients
DDRi Summit 2025: Monitoring of DNA Damage Response Biomarkers using Circulating Tumour Cells captured with ANGLE’s Parsortix® instrument from Ovarian, Prostate, and Breast cancer patients
EACR LBx 24 – Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples.
Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer
DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays
Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C‑ProMeta‑1)
Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer